Jasper Therapeutics (NASDAQ:JSPRW – Get Free Report) is projected to issue its results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.08) per share and revenue of $12.00 million for the quarter.
Jasper Therapeutics Price Performance
NASDAQ:JSPRW opened at $0.00 on Thursday. Jasper Therapeutics has a 1-year low of $0.00 and a 1-year high of $0.15.
Jasper Therapeutics Company Profile
Jasper Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for diseases involving hematopoietic stem cells, bone marrow transplantation and immune system disorders. The company’s research has centered on antibody-based medicines designed to enable or improve stem cell transplantation and gene therapy procedures.
Jasper’s leading investigational product is briquilimab, formerly known as JSP191. Briquilimab is a monoclonal antibody that targets CD117, a receptor involved in the survival and maintenance of hematopoietic stem cells.
Further Reading
- Five stocks we like better than Jasper Therapeutics
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
